Once-weekly NNC0195-0092 (somapacitan) trial compares efficacy and safety against daily Norditropin in GHD children
Background
For children diagnosed with Growth Hormone Deficiency (GHD), daily subcutaneous injections of recombinant human growth hormone (rhGH) are the standard treatment. While effective, the burden of daily injections can significantly impact patient adherence, leading to suboptimal treatment outcomes and reduced final adult height. This challenge highlights an unmet need for less frequent, equally efficacious, and safe treatment options. NNC0195-0092, also known as somapacitan, is a long-acting rhGH analog designed for once-weekly administration, aiming to improve patient convenience and adherence by reducing injection frequency.
Study Design
This global, randomized, open-label, active-controlled Phase 3 trial is designed to investigate the efficacy and safety of once-weekly NNC0195-0092 compared to daily growth hormone treatment using Norditropin® FlexPro® (a daily rhGH formulation). The study population consists of growth hormone treatment-naïve pre-pubertal children diagnosed with Growth Hormone Deficiency. Participants will undergo a main treatment period of 26 weeks, followed by an additional 26-week extension period. The primary endpoints include assessing growth velocity and safety profiles, aiming to determine if the once-weekly regimen can match the established efficacy of daily injections while maintaining a comparable safety profile.
Results
This trial description outlines the study design and objectives; however, specific efficacy and safety results for NNC0195-0092 compared to daily Norditropin® FlexPro® are not yet available in the provided abstract. The study is designed to assess primary endpoints related to annualized height velocity (AHV), changes in height standard deviation score (SDS), and comprehensive safety profiles over a 26-week main treatment period, followed by an extension. Key outcomes will include insulin-like growth factor 1 (IGF-1) levels, bone age progression, and the incidence of adverse events. Future publications will detail the statistical significance and clinical impact of once-weekly somapacitan on Growth Hormone Deficiency in pre-pubertal children, addressing the potential for improved adherence and patient quality of life with a less frequent dosing regimen.
Why It Matters
A successful once-weekly growth hormone treatment like NNC0195-0092 could significantly transform the management of Growth Hormone Deficiency in children. Improved adherence to treatment regimens is a critical factor in achieving optimal growth outcomes, and reducing injection frequency from daily to weekly could substantially lessen the psychological and practical burden on children and their families. This could lead to better long-term growth, enhanced quality of life, and reduced treatment-related stress. If proven efficacious and safe, once-weekly somapacitan could become a preferred protocol, simplifying administration and potentially increasing the overall effectiveness of GHD therapy by ensuring more consistent patient compliance.